ProfileGDS5678 / 1432409_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 33% 35% 34% 35% 36% 34% 34% 35% 34% 35% 35% 35% 34% 35% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7866233
GSM967853U87-EV human glioblastoma xenograft - Control 22.7895535
GSM967854U87-EV human glioblastoma xenograft - Control 32.7841134
GSM967855U87-EV human glioblastoma xenograft - Control 42.7344135
GSM967856U87-EV human glioblastoma xenograft - Control 52.7756836
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8525734
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8358134
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7950635
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7536234
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7791435
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7784735
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7592235
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7759234
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7848235